Skip to main content
Download PDF

Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats

Critical Care volume 14, Article number: R165 (2010) Cite this article

Abstract

Introduction

Hydrogen sulfide (H2S) has been shown to improve survival in rodent models of lethal hemorrhage. Conversely, other authors have reported that inhibition of endogenous H2S production improves hemodynamics and reduces organ injury after hemorrhagic shock. Since all of these data originate from unresuscitated models and/or the use of a pre-treatment design, we therefore tested the hypothesis that the H2S donor, sodium hydrosulfide (NaHS), may improve hemodynamics in resuscitated hemorrhagic shock and attenuate oxidative and nitrosative stresses.

Methods

Thirty-two rats were mechanically ventilated and instrumented to measure mean arterial pressure (MAP) and carotid blood flow (CBF). Animals were bled during 60 minutes in order to maintain MAP at 40 ± 2 mm Hg. Ten minutes prior to retransfusion of shed blood, rats randomly received either an intravenous bolus of NaHS (0.2 mg/kg) or vehicle (0.9% NaCl). At the end of the experiment (T = 300 minutes), blood, aorta and heart were harvested for Western blot (inductible Nitric Oxyde Synthase (iNOS), Nuclear factor-κB (NF-κB), phosphorylated Inhibitor κB (P-IκB), Inter-Cellular Adhesion Molecule (I-CAM), Heme oxygenase 1(HO-1), Heme oxygenase 2(HO-2), as well as nuclear respiratory factor 2 (Nrf2)). Nitric oxide (NO) and superoxide anion (O2-) were also measured by electron paramagnetic resonance.

Results

At the end of the experiment, control rats exhibited a decrease in MAP which was attenuated by NaHS (65 ± 32 versus 101 ± 17 mmHg, P < 0.05). CBF was better maintained in NaHS-treated rats (1.9 ± 1.6 versus 4.4 ± 1.9 ml/minute P < 0.05). NaHS significantly limited shock-induced metabolic acidosis. NaHS also prevented iNOS expression and NO production in the heart and aorta while significantly reducing NF-kB, P-IκB and I-CAM in the aorta. Compared to the control group, NaHS significantly increased Nrf2, HO-1 and HO-2 and limited O2- release in both aorta and heart (P < 0.05).

Conclusions

NaHS is protective against the effects of ischemia reperfusion induced by controlled hemorrhage in rats. NaHS also improves hemodynamics in the early resuscitation phase after hemorrhagic shock, most likely as a result of attenuated oxidative stress. The use of NaHS hence appears promising in limiting the consequences of ischemia reperfusion (IR).

Introduction

Hemorrhagic shock (HS) is a life-threatening complication in both trauma patients and in the operating room [1, 2]. The pathophysiology of HS is complex, especially during the reperfusion phase [3]. During HS, the state of vasoconstriction turns into vasodilatory shock. According to Landry et al. [4], this phenomenon is related to tissue hypoxia as well as to a proinflammatory immune response [4]. In addition, during the reperfusion phase, cellular injuries induced by ischemia are enhanced, and are associated with excessive production of radical oxygen species (ROS), leading to a further systemic inflammatory response [5].

Hydrogen sulfide (H2S), is known as an environmental toxic gas [6], but has also recently been recognized as a gasotransmitter [7], similar to nitric oxide (NO) and carbon monoxide (CO). H2S is endogenously synthesized [8] and may play a crucial role in critical care according to the recent review of Wagner et al. in 2009 [9]. Depending on the selected models, H2S has been reported to exhibit pro- and anti-inflammatory properties and to display opposite effects in various shock conditions [10–13]. H2S has also been reported to induce direct inhibition of endothelial nitric oxide synthase (eNOS) [14]. However, this effect was linked to the concentration of H2S, whereby H2S caused contraction at low doses and relaxation at high doses in both rat and mouse aorta precontracted by phenylephrine [14]. This dual effect was related, at low dosage, to the inhibition of the conversion of citrulline into arginine by eNOS (contraction) and at high dosage by activation of K+ATP channels or due to NO quenching [15]. Blackstone et al. [10, 11] recently suggested that inhalation of H2S induced a "suspended animation-like" state which protected animals from lethal hypoxia. Furthermore, Morrison et al. [16] demonstrated that pre-treatment with inhaled or intravenous (i.v.) H2S prevented death and lethal hypoxia in rats subjected to controlled but unresuscitated hemorrhage.

Conversely, Mok et al. [17] reported the hemodynamic effects of the inhibition of H2S synthesis, along with a rapid restoration in mean arterial pressure (MAP) and heart rate (HR), in a model of unresuscitated hemorrhage in rats.

As the vascular effects of H2S are still a matter of debate, and since all of these data originated from unresuscitated hemorrhage, we therefore tested the hypothesis that the H2S donor sodium hydrosulfide (NaHS), infused before retransfusion in a model of a controlled hemorrhagic rat, may improve hemodynamics and attenuate oxidative and nitrosative stresses, as well as the inflammatory response during reperfusion. Since the role of the cardiovascular system during shock becomes critical, we therefore focused on the inflammatory response as well as on the oxidative and nitrosative stresses in the heart and aorta.

Materials and methods

The animal protocol was approved by the regional animal ethics committee (CREEA-Nantes, France). The experiments were performed in compliance with the European legislation on the use of laboratory animals.

Animals

Adult male Wistar rats, weighing 325 ± 15 g, were housed with 12-hour light/dark cycles in the animal facility of the University of Angers (France).

Surgical procedure

Animals were anesthetized with intraperitoneal pentobarbital (50 mg/kg of body weight) and placed on a homeothermic blanket system in order to maintain rectal temperature between 36.8°C and 37.8°C throughout the experiment. After local anesthesia with lidocaine 1% (Lidocaine® 1% AstraZeneca, Reuil-Malmaison, France), a tracheotomy was performed. Animals were mechanically ventilated (Harvard Rodent 683 ventilator, Harvard Instruments, South Natick, MA, USA) and oxygen was added in order to maintain PaO2 above 100 mmHg. The left carotid artery was exposed, and a 2.0 mm transit-time ultrasound flow probe (Transonic Systems Inc., Ithaca, NY, USA) was attached to allow continuous measurement of blood flow (CBF).

After local anesthesia, the femoral artery was canulated both to measure MAP and HR and for the induction of hemorrhagic shock. The homolateral femoral vein was canulated for retransfusion of shed blood, for fluid maintenance and for bolus infusion (either vehicle or NaHS).

Induction of hemorrhagic shock and protocol design

After a 20-minute stabilization period, controlled hemorrhage [18] was induced by withdrawing approximately 9 ml of blood collected in a heparinized syringe (200 UI) within 10 minutes until MAP decreased to 40 ± 2 mmHg. This state of controlled hemorrhage was maintained during 60 minutes by further blood withdrawal or reinfusion of shed blood. Ten minutes prior to retransfusion time, rats were randomly allocated to receive either NaHS (single i.v. bolus 0.2 mg/kg body weight) or control (vehicle 0.9% NaCl), and designated as HS-NaHS (n = 11) and HS-saline (n = 11) respectively. After 60 minutes of shock, shed blood was retransfused within 10 minutes. Animals were continuously monitored for HR, MAP and CBF during 300 minutes. At the end of the experiment, the rats were sacrificed and blood samples were collected for measurement of arterial lactate levels. Aorta and hearts were harvested and maintained in liquid nitrogen for further in vitro analyses (Western blotting, superoxide anion and NO production) (Figure 1).

Figure 1
figure 1

Design of the protocol (in case of hemorrhagic shock).

Full size image

Two additional groups of rats were managed in the same manner as the other animals but were not bled. One group (control-NaHS, n = 5) received a single bolus of NaHS (0.2 mg/kg body weight) while the other group received the vehicle (0.9% NaCl 0.2 mg/kg body weight) (control-saline n = 5) in order to assess the hemodynamic effects of NaHS in normal rats.

Maintenance of fluid was performed with a perfusion of 1.2 ml per hour of 0.9% NaCl in all groups.

Hydrogen sulfide donor preparation

The dehydrated NaHS powder (sodium hydrogen sulfide, anhydrous, 2 g, Alpha Aesar GmbH & Co, UK) was dissolved in isotonic saline under argon gas bubbling, until a concentration of 40 mM was achieved. Intravenous (i.v.) administration was preferred to the inhaled form of H2S, as it represented an easier route whilst avoiding side effects such as airway irritation. In accordance with pilot experimentations in our laboratory and a previous study [19], a single intravenous bolus of NaHS (0.2 mg/kg) was infused.

Monitoring and measurements

Arterial blood gases were controlled after the stabilization period in order to adjust mechanical ventilation. Blood gases, acid-base status and blood glucose were recorded at baseline (t = 0 minute), at the end of retransfusion (t = 70 minutes) and at the end of the experiment (t = 300 minutes). MAP, HR, CBF and temperature were recorded during the stabilization period (baseline) and every 10 minutes during the observation period.

In vitromeasurements

Determination by electron paramagnetic resonance (EPR) NO spin trapping

Aorta and heart samples were incubated for 30 minutes in Krebs-Hepes buffer containing: BSA (20.5 g/L), CaCl2 (3 mM) and L-Arginine (0.8 mM). N, N D-Ethyldithiocarbamate and Fe3+ citrate complex (FeDETC) (3.6 mg) and FeSO4.7H2O (2.25 mg) were separately dissolved under N2 gas bubbling in 10 ml volumes of ice-cold Krebs-Hepes buffer. These compounds were rapidly mixed to obtain a pale yellow-brown opalescent colloid Fe(DETC)2 solution (0.4 mM), which was used immediately. The colloid Fe(DETC)2 solution was added to the organs and incubated for 45 minutes at 37°C. Thereafter, the organs were snap frozen in plastic tubes using liquid N2. NO measurement was performed on a table-top x-band spectrometer Miniscope (Magnettech, MS200, Berlin, Germany). Recordings were performed at 77°K, using a Dewar flask. Instrument settings were: microwave power, 10 mW; amplitude modulation, 1 mT; modulation frequency, 100 kHz; sweep time, 60 s and number of scans, 5. Levels of NO were expressed as amplitude of signal in unit per weight of dried sample (Amplitude/Wd).

Superoxide anion (O2-) spin-trapping

Aorta and heart samples were allowed to equilibrate in deferoxamine-chelated Krebs-Hepes solution containing 1 hydroxy-3methoxycarbonyl 2,2,5,5-tetramethylpyrrolidin (CMH, Noxygen, Germany) (500 μM), deferoxamine (25 μM) and DETC (5 μM) under constant temperature (37°C) for one hour. The reaction was stopped by placing the samples in ice, subsequently frozen in liquid N2 and analyzed in a Dewar flask by EPR spectroscopy (Magnettech, MS200, Berlin, Germany).. The instrument settings were as follows: temperature, 77° K; microwave power, 1 mW; amplitude modulation, 0.5 mT; sweep time, 60 s; field sweep, 60 G. Values were expressed in signal amplitude/mg weight of dried tissue (Amplitude/Wd).

Western blotting

Aorta and heart samples were homogenized in lysis buffer (0.5 M Tris-HCl, 1.86 g/ml EDTA, 1 M NaCl, 0.001 g/ml Digitonin, 4 U/ml Aprotinin, 2 μM Leupeptin, 100 μM phenylmethylsulfonyl fluoride (PMSF)). Proteins (20 μg) were separated on 10% SDS-PAGE and transferred onto nitrocellulose membranes. Blots were probed by an over-night incubation (4°C) with a mouse anti-inducible NOS (iNOS) antibody (BD Biosciences, San Jose, CA, USA), a polyclonal rabbit nuclear factor NF-kB p65 antibody (Abcam, Cambridge, UK), a mouse anti-human phosphorylated (ser32/36)-IkB alpha (P-IkBa) antibody (US Biologica, Swampscott, Massachusetts, USA), an anti-rat I-CAM/CD54 antibody (R&D Systems), a goat COX-1(M-20) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), a goat COX-2 antibody (Santa Cruz Biotechnology), a rabbit polyclonal nuclear respiratory factor Nrf2 (C-20) antibody (Santa Cruz Biotechnology), a rabbit anti-heme-oxygenase-1 (HO-1) polyclonal antibody (Stressgen Bioreagents, San Diego California, USA) or a rabbit anti-heme-oxygenase-2 (HO-2) polyclonal antibody (Stressgen Bioreagents, San Diego California, USA). Membranes were washed and incubated for one hour at room temperature with a secondary anti-mouse, anti-rabbit or anti-goat peroxidase-conjugated IgG (Promega, Madison, WI, USA).

Blots were visualized using an enhanced chemiluminescence system (ECL Plus; Amersham, Buckinghamshire, UK), after which the membranes were probed again with a polyclonal rabbit anti-β-actin antibody (Sigma-Aldrich, Saint Quentin Fallavier, France) for densitometric quantification and normalization to β-actin expression.

Data analysis

For repeated measurements, one-way analysis of variance was used to evaluate within-group differences. Difference between groups was tested using a two-way analysis of variance (repeated time measurements and treatments as independent variables). When the relevant F values were significant at the 5% level, further pairwise comparisons were performed using the Dunnett's test for the effect of time and with Bonferroni's correction for the effects of treatment at specific times. The Mann-Whitney test was used for inter-group comparisons for Western blotting, NO and O2- signal measurements. All values are presented as mean ± SD for n experiments (n representing the number of animals). All statistics were performed with the Statview software (version 5.0; SAS Institute, Cary, NC, USA). A P-value < 0.05 was considered statistically significant.

Results

The hydrogen sulfide donor, NaHS, prevents ischemia-reperfusion (I/R)-induced hemodynamic dysfunction

There was no significant difference in hemodynamic parameters at baseline (Table 1, Figure 2). Both hemorrhage groups were similarly bled (9.2 ± 1.8 mL versus 9.2 ± 1.6 mL for HS-saline and HS-NaHS respectively). While HR was unaffected, MAP and CBF remained significantly decreased after controlled HS despite retransfusion of shed blood, although this effect was significantly (P < 0.05) attenuated in HS-NaHS-treated animals (Figure 2). All HS-NaHS-treated animals survived, whereas 5 animals out of 11 died in the HS-saline group within five hours of experimentation from refractory hypotension. The mean survival time in the HS-saline group was 230 ± 89 minutes. Arterial pH and base excess were similar at baseline.

Table 1 Hemodynamic and acid-base measurements
Full size table
Figure 2
figure 2

Hemodynamic measurements. Mean arterial blood pressure (MAP) and carotid blood flow (CBF) in hemorrhagic shock (HS)/saline group (white circle) and hemorrhagic shock/NaHS group (black circle) rats recorded during 300 minutes monitoring period. Data are expressed as mean ± SD of n = 11 rats for HS/NaHS group, n = 11 rats for HS/saline group. *P < 0.05, significantly different between HS-saline and HS-NaHS groups.

Full size image

Compared to the control group, NaHS significantly limited the decrease in pH during the reperfusion period (P < 0.05) (Table 1). In both control-saline and control-NaHS groups, hemodynamics remained unaltered (MAP, CBF and HR), as was arterial pH. Hence, EPR and Western blot analysis were not performed in these groups.

NaHS prevents I/R-dependent iNOS expression and NO overproduction in cardiovascular tissues

Compared to the HS-saline group, NaHS treatment in hemorrhagic rats prevented I/R-induced NO overproduction in the aorta and heart (P < 0.05) (Figure 3a, c). In agreement with these data, a decreased iNOS protein concentration was found in both aorta and heart in the HS-NaHS group (Figure 3b, d).

Figure 3
figure 3

NaHS administration reduces NO production and iNOS expression in aorta and heart. (a, c) Quantification of the amplitude of NO-Fe(DETC)2 signal in unit/weight (mg of the dried sample Amplitude/Wd, n = 10) in the aorta (a) and heart (c) of the two groups of rats. (b, d) Western blots revealing iNOS expression in the in the whole lysate of aortas (n = 6) (b) and in hearts (n = 6) (d) of two groups of rats. Densitometric analysis was used to calculate normalized protein ratio (protein to β-actin). Data are expressed as mean ± SD. *P < 0.05, significantly different between HS-saline and HS-NaHS groups.

Full size image

NaHS reduces I/R-induced up-regulation of cardiovascular phosphorylated I-κB and cell adhesion molecules in aorta

Compared to the HS-saline group, NaHS significantly decreased P-IκB and protein concentrations in the aorta (Figure 4a) and heart (Figure 4e) whereas NF-κB decreased only in the heart (Figure 4d). In addition, HS-NaHS treated rats showed a significant decrease in blotting for I-CAM in aorta (Figure 4c) but not in heart (P < 0.05) in comparison to the HS-saline group (Figure 4f).

Figure 4
figure 4

Effects of NaHS on inflammatory pathway signaling. (a, d) Western blots revealing NF-kB expression in the aorta (a) and in the heart (d). (b, e) Western blots revealing P-IκB expression in aorta (b) and in heart (e). (c, f) Western blots revealing I-CAM expression in aorta (c) and in heart (f). Proteins are expressed in the whole lysate of aorta (n = 6) and heart (n = 6) from two groups of rats. Densitometric analysis was used to calculate normalized protein ratio (protein to β-actin). Data are expressed as mean ± SD. *P < 0.05, significantly different between HS-saline and HS-NaHS groups.

Full size image

NaHS reduces I/R-induced oxidative stress

Compared to the HS-saline group, Nrf2 was increased in aorta (P < 0.05) (Figure 5a) concomitant with a subsequent increase in HO-1 and HO-2 expressions (Figure 5b, c). However, NaHS did not decrease Nrf2, HO-1 and HO-2 (data not shown) in heart of the HS-NaHS group. Finally, compared to the HS-saline group, NaHS limited O2- release in both tissues (P < 0.05) (Figure 5d, e).

Figure 5
figure 5

Effects of NaHS on antioxidant pathway. (a, b, c) Western blots revealing in aorta Nrf2 (a), HO-1 (b) and HO-2 (c) in the whole lysate of aortas (n = 6). (d, e) Quantification of the amplitude of O2--Fe(DETC)2 signal in unit/weight (mg of the dried sample Amplitude/Wd, n = 10) in the aorta (d) and heart (e) of the two groups of rats. Data are expressed as mean ± SD. *P < 0.05 and **P < 0.01, significantly different between HS-saline and HS-NaHS groups.

Full size image

Discussion

In the present study, we report the beneficial effects of NaHS as an H2S donor, prior to retransfusion, in a rodent model of controlled hemorrhage. The key findings were that a single i.v. NaHS bolus immediately before retransfusion of shed blood (i) limited the I/R induced-decrease in MAP and (ii) was associated with reduced inflammatory and oxidative stress responses.

Although H2S is usually considered as an endogenous vasodilatator, this effect nevertheless remains a matter of debate. At low concentrations (10 to 100 μM H2S), Ali et al. [15] found a vasoconstrictor effect of H2S on rodent aorta, whereas Dombkovski [20] reported that H2S was responsible for either vasodilatation or vasoconstriction, according to species and organ requirements. Furthermore, data reported in the literature are highly conflicting: indeed, Mok et al. [17] reported an increase in MAP in unresuscitated HS treated with H2S synthesis blockers (DL-propargylglycine and μ-cyanoalanine) whereas Morrison et al. [16], using an opposite experimental approach, reported beneficial effects of H2S on survival in rats submitted to lethal unresuscitated HS. In the present study, compared to the HS-saline group, a single i.v. bolus of NaHS produced a substantial increase in MAP in hemorrhagic rats. All rats were well oxygenated (PaO2 >100 mm Hg, data not shown), an observation that was not reported in the studies by Mok et al. [17] and Morrison et al. [16].

The absence of a detrimental effect on stroke volume has already been reported by others [11, 21, 22]. Herein, heart rate was not altered in either group while carotid blood flow was higher in the HS-NaHS group. Since blood flow was decreased in HS-saline, this would suggest a higher stroke volume in HS-NaHS treated rats, although this conclusion could be challenged since cardiac output was not directly measured in this study. Nevertheless, this result is in agreement with improved ejection fraction in a model of myocardial I/R injury [23].

In the present study, NaHS treatment limited the metabolic acidosis induced by I/R. Simon et al. [21] also reported similar metabolic effects in pigs. Whether this effect is due to reduced metabolic demand induced by the sulfide donor or to a direct effect on mitochondrial K+ATP channels remains speculative since metabolic rate was not measured.

It is well documented that cardiovascular dysfunction during I/R is partly linked to the activation of the NF-κB/Rel pathway. This mechanism has been demonstrated in recent investigations [24], allowing the expression of iNOS and subsequent overproduction of NO in cardiovascular tissues [25]. As reported by others [26], we show herein that NaHS induced an in vivo down-expression of iNOs, with subsequent decrease in NO overproduction.

The effects of H2S on inflammation are also a matter of contention [25, 27, 28]. In the present model, we report a predominant inflammatory modulation effect. Indeed, NaHS was found to limit cardiovascular NF-κB activation as well as decrease I-CAM expression in aorta. These results confirm in vitro experiments which demonstrated that NaHS as well as other H2S endogenous donors modulate leukocyte-mediated inflammation [25, 29] by decreasing leukocyte adhesion and leukocyte infiltration [23] through activation of K+ATP channels [25].

In the present study, infusion of a NaHS bolus attenuated oxidative stress induced by I/R, as mirrored by a decreased release of O2- in tissues. H2S is known to react with the four different reactive oxygen species [30–32]. Since increased ROS formation is implicated in lipid peroxidation and oxidation of thiol groups, H2S, by decreasing ROS overproduction, may in fact limit tissue damage. Our results show that O2- production was decreased in both aorta and heart, suggesting a protective effect on cardiovascular tissues. These results are in agreement with the observations of Sivarajah et al. [33], who recently reported that the cardioprotective effects of NaHS in a model of I/R on isolated cardiomyocytes were related to antioxidative and anti-nitrosative properties.

Nrf2 could contribute to adaptive and cytoprotective responses to various cell damages [31, 34]. Different antioxidant cellular pathways are associated with Nrf2 expression such as the heme oxygenase enzymes, HO-1 and HO-2. Indeed, Maines et al. [30] reported increased levels of HO-1 in I/R injuries; moreover, HO-1 was found to improve resistance to oxidative stress [32] and modulate inflammatory response, particularly in hemorrhagic shock [35]. HO-2, meanwhile, is found in almost all tissues and is known as a potential O2 sensor in addition to playing a role in the maintenance of vascular tone [32]. Conversely to aortic tissues, there were no changes in Nrf2, HO-1 or HO-2 in the heart samples. In the present experimental design, rats were anesthetized and warmed but not overheated for ethical reasons in accordance with our animal care regulatory agency. The metabolic rate was not measured. In the studies of Blackstone et al. [10, 11] and Morisson et al. [16], animals were awake. The difference between the two experimental protocols does not exclude a metabolic effect in our experiments. However, since body temperature remained constant throughout the study period, the putative effect of hypothermia did not significantly contribute to the observed results, which are related to reduced inflammatory and oxidative stress pathways. Consequently, the beneficial effect of NaHS is unlikely the result of a hibernation-like metabolic state of "suspended animation" as reported previously [10, 11, 16, 22]. The present observation, however, confirms other studies in which H2S donors NaHS and Na2S protected against ischemia reperfusion injury [23, 33, 36–41] and burn injury [29] independently of core temperature.

Study limitations

The present study has several limitations. By design, in order to mimic a realistic emergency clinical situation, we used a single i.v. dose of NaHS. Indeed, given the potential harmful effects of H2S on cytochrome c and the lack of data pertaining to the ideal target dose in the literature, we chose to infuse a single bolus dose of H2S. Since a dose-response study was not performed, it is possible that we may have missed toxic or beneficial potential effects of the hydrogen sulfide donor.

Moreover, we did not assess the effects of NaHS on inflammation and oxidative stress in non hemorrhagic rats since the injection of a single dose of 0.2 mg/kg of NaHS did not alter mean arterial pressure or carotid blood flow. The absence of vascular effects in non hemorrhagic rats may be related to the low infused dose or to the opposite effects of NaHS on isolated arteries. NaHS has been reported to exert a contractile activity mediated by the inhibition of nitric oxide and endothelial-derived hyperpolarizing factor pathways as well as a relaxation through both K+ATP channel-dependent and -independent pathways. In addition, Kubo et al. [14] reported only a very brief and reversible decrease in MAP (100 seconds) after i.v. injection of NaHS at 28 μmol/kg, which is equal to 0.31 mg/kg, a value close to the dose used in the present study. One could speculate that the beneficial effects of NaHS are unveiled in I/R situations when iNOS is up-regulated.

Conclusions

The present in vivo experimental study of I/R following resuscitated hemorrhagic shock in rats demonstrates that a single i.v. bolus of NaHS limited the decrease in MAP during early reperfusion and down-regulated NF-κB, iNOS and I-CAM expressions. These anti-inflammatory effects were associated with decreased NO and O2- production. Such beneficial effects of H2S donors warrant further experimental studies.

Key messages

  • The results of this in vivo experimental study demonstrate that a single i.v. bolus of hydrogen sulfide (considered as the third gaseous transmitter) donor, NaHS, prevented ischemia reperfusion (I/R)-induced hemodynamic dysfunction in a model of controlled hemorrhage in rats.

  • NaHS reduced NO production and I/R-dependent iNOS expression and improved metabolic dysfunction.

  • NaHS down-regulated NF-κB, iNOS and I-CAM expressions in this model.

  • NaHS reduced I/R-induced oxidative stress.

Abbreviations

CBF:

carotid blood flow

CO:

carbon monoxide

eNOS:

endothelial nitric oxide synthase

EPR:

electron paramagnetic resonance

FeDETC:

N, N D-Ethyldithiocarbamate and Fe3+ citrate complex HO-1: heme-oxygenase-1

HO-2:

heme-oxygenase-2

HR:

heart rate

HS:

hemorrhagic shock

H2S:

hydrogen sulfide

iNOS:

inducible NOS

I/R:

ischemia-reperfusion

i.v.:

intravenous

MAP:

mean arterial pressure

NaHS:

sodium hydrosulfide

NO:

nitric oxide

Nrf2:

nuclear respiratory factor 2

O2:

superoxide anion

PI-κB:

phosphorylated I-κB

PMSF:

phenylmethylsulfonyl fluoride

ROS:

radical oxygen species

SD:

standard deviation.

References

  1. Kauvar DS, Lefering R, Wade CE: Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006, 60: S3-11. 10.1097/01.ta.0000199961.02677.19.

    Article  PubMed  Google Scholar 

  2. Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, Pons PT: Epidemiology of trauma deaths: a reassessment. J Trauma. 1995, 38: 185-193. 10.1097/00005373-199502000-00006.

    Article  CAS  PubMed  Google Scholar 

  3. Rushing GD, Britt LD: Reperfusion injury after hemorrhage: a collective review. Ann Surg. 2008, 247: 929-937. 10.1097/SLA.0b013e31816757f7.

    Article  CAS  PubMed  Google Scholar 

  4. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med. 2001, 345: 588-595. 10.1056/NEJMra002709.

    Article  CAS  PubMed  Google Scholar 

  5. Collard CD, Gelman S: Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology. 2001, 94: 1133-1138. 10.1097/00000542-200106000-00030.

    Article  CAS  PubMed  Google Scholar 

  6. Couch L, Martin L, Rankin N: Near death episode after exposure to toxic gases from liquid manure. N Z Med J. 2005, 118: U1414-

    PubMed  Google Scholar 

  7. Wang R: Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?. FASEB J. 2002, 16: 1792-1798. 10.1096/fj.02-0211hyp.

    Article  CAS  PubMed  Google Scholar 

  8. Lowicka E, Beltowski J: Hydrogen sulfide (H2S) - the third gas of interest for pharmacologists. Pharmacol Rep. 2007, 59: 4-24.

    CAS  PubMed  Google Scholar 

  9. Wagner F, Asfar P, Calzia E, Radermacher P, Szabo C: Bench-to-bedside review: Hydrogen sulfide - the third gaseous transmitter: applications for critical care. Crit Care. 2009, 13: 213-10.1186/cc7700.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Blackstone E, Morrison M, Roth MB: H2S induces a suspended animation-like state in mice. Science. 2005, 308: 518-10.1126/science.1108581.

    Article  CAS  PubMed  Google Scholar 

  11. Blackstone E, Roth MB: Suspended animation-like state protects mice from lethal hypoxia. Shock. 2007, 27: 370-372. 10.1097/SHK.0b013e31802e27a0.

    Article  CAS  PubMed  Google Scholar 

  12. Szabo C: Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007, 6: 917-935. 10.1038/nrd2425.

    Article  CAS  PubMed  Google Scholar 

  13. Zhang H, Zhi L, Moore PK, Bhatia M: Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse. Am J Physiol Lung Cell Mol Physiol. 2006, 290: L1193-L1201. 10.1152/ajplung.00489.2005.

    Article  CAS  PubMed  Google Scholar 

  14. Kubo S, Kurokawa Y, Doe I, Masuko T, Sekiguchi F, Kawabata A: Hydrogen sulfide inhibits activity of three isoforms of recombinant nitric oxide synthase. Toxicology. 2007, 241: 92-97. 10.1016/j.tox.2007.08.087.

    Article  CAS  PubMed  Google Scholar 

  15. Ali MY, Ping CY, Mok YY, Ling L, Whiteman M, Bhatia M, Moore PK: Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide?. Br J Pharmacol. 2006, 149: 625-634. 10.1038/sj.bjp.0706906.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Morrison ML, Blackwood JE, Lockett SL, Iwata A, Winn RK, Roth MB: Surviving blood loss using hydrogen sulfide. J Trauma. 2008, 65: 183-188. 10.1097/TA.0b013e3181507579.

    Article  CAS  PubMed  Google Scholar 

  17. Mok YY, Atan MS, Yoke PC, Zhong JW, Bhatia M, Moochhala S, Moore PK: Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis. Br J Pharmacol. 2004, 143: 881-889. 10.1038/sj.bjp.0706014.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Wiggers C: Present status of shock problem. Physiol Rev. 1942, 22: 74-123.

    Google Scholar 

  19. Meziani F, Kremer H, Tesse A, Baron-Menguy C, Mathien C, Mostefai HA, Carusio N, Schneider F, Asfar P, Andriantsitohaina R: Human serum albumin improves arterial dysfunction during early resuscitation in mouse endotoxic model via reduced oxidative and nitrosative stresses. Am J Pathol. 2007, 171: 1753-1761. 10.2353/ajpath.2007.070316.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Dombkowski RA, Russell MJ, Schulman AA, Doellman MM, Olson KR: Vertebrate phylogeny of hydrogen sulfide vasoactivity. Am J Physiol Regul Integr Comp Physiol. 2005, 288: R243-R252.

    Article  CAS  PubMed  Google Scholar 

  21. Koenitzer JR, Isbell TS, Patel HD, Benavides GA, Dickinson DA, Patel RP, Darley-Usmar VM, Lancaster JR, Doeller JE, Kraus DW: Hydrogen sulfide mediates vasoactivity in an O2-dependent manner. Am J Physiol Heart Circ Physiol. 2007, 292: H1953-H1960. 10.1152/ajpheart.01193.2006.

    Article  CAS  PubMed  Google Scholar 

  22. Simon F, Giudici R, Duy CN, Schelzig H, Oter S, Groger M, Wachter U, Vogt J, Speit G, Szabo C, Radermacher P, Calzia E: Hemodynamic and metabolic effects of hydrogen sulfide during porcine ischemia/reperfusion injury. Shock. 2008, 30: 359-364. 10.1097/SHK.0b013e3181674185.

    Article  CAS  PubMed  Google Scholar 

  23. Volpato GP, Searles R, Yu B, Scherrer-Crosbie M, Bloch KD, Ichinose F, Zapol WM: Inhaled hydrogen sulfide: a rapidly reversible inhibitor of cardiac and metabolic function in the mouse. Anesthesiology. 2008, 108: 659-668. 10.1097/ALN.0b013e318167af0d.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, Kimura H, Chow CW, Lefer DJ: Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci USA. 2007, 104: 15560-15565. 10.1073/pnas.0705891104.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Oh GS, Pae HO, Lee BS, Kim BN, Kim JM, Kim HR, Jeon SB, Jeon WK, Chae HJ, Chung HT: Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med. 2006, 41: 106-119. 10.1016/j.freeradbiomed.2006.03.021.

    Article  CAS  PubMed  Google Scholar 

  26. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL: Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006, 20: 2118-2120. 10.1096/fj.06-6270fje.

    Article  CAS  PubMed  Google Scholar 

  27. Kubo S, Doe I, Kurokawa Y, Nishikawa H, Kawabata A: Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of vascular tension. Toxicology. 2007, 232: 138-146. 10.1016/j.tox.2006.12.023.

    Article  CAS  PubMed  Google Scholar 

  28. Jeong SO, Pae HO, Oh GS, Jeong GS, Lee BS, Lee S, Kim DY, Rhew HY, Lee KM, Chung HT: Hydrogen sulfide potentiates interleukin-1β-induced nitric oxide production via enhancement of extracellular signal-regulated kinase activation in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 2006, 345: 938-944. 10.1016/j.bbrc.2006.05.002.

    Article  CAS  PubMed  Google Scholar 

  29. Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW, Zhao Y, Baskar R, Tan CH, Moore PK: Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation. 2008, 117: 2351-2360. 10.1161/CIRCULATIONAHA.107.753467.

    Article  CAS  PubMed  Google Scholar 

  30. Esechie A, Kiss L, Olah G, Horvath EM, Hawkins H, Szabo C, Traber DL: Protective effect of hydrogen sulfide in a murine model of acute lung injury induced by combined burn and smoke inhalation. Clin Sci (Lond). 2008, 115: 91-97. 10.1042/CS20080021.

    Article  CAS  Google Scholar 

  31. Maines MD, Mayer RD, Ewing JF, McCoubrey WK: Induction of kidney heme oxygenase-1 (HSP32) mRNA and protein by ischemia/reperfusion: possible role of heme as both promotor of tissue damage and regulator of HSP32. J Pharmacol Exp Ther. 1993, 264: 457-462.

    CAS  PubMed  Google Scholar 

  32. Scarpulla RC: Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev. 2008, 88: 611-638. 10.1152/physrev.00025.2007.

    Article  CAS  PubMed  Google Scholar 

  33. Wagener FA, Volk HD, Willis D, Abraham NG, Soares MP, Adema GJ, Figdor CG: Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev. 2003, 55: 551-571. 10.1124/pr.55.3.5.

    Article  CAS  PubMed  Google Scholar 

  34. Sivarajah A, Collino M, Yasin M, Benetti E, Gallicchio M, Mazzon E, Cuzzocrea S, Fantozzi R, Thiemermann C: Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock. 2009, 31: 267-274. 10.1097/SHK.0b013e318180ff89.

    Article  CAS  PubMed  Google Scholar 

  35. Huang HC, Nguyen T, Pickett CB: Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem. 2002, 277: 42769-42774. 10.1074/jbc.M206911200.

    Article  CAS  PubMed  Google Scholar 

  36. Tamion F, Richard V, Bonmarchand G, Leroy J, Lebreton JP, Thuillez C: Induction of heme-oxygenase-1 prevents the systemic responses to hemorrhagic shock. Am J Respir Crit Care Med. 2001, 164: 1933-1938.

    Article  CAS  PubMed  Google Scholar 

  37. Tripatara P, Sa PN, Collino M, Gallicchio M, Kieswich J, Castiglia S, Benetti E, Stewart KN, Brown PA, Yaqoob MM, Fantozzi R, Thiemermann C: Generation of endogenous hydrogen sulfide by cystathionine-γ-lyase limits renal ischemia/reperfusion injury and dysfunction. Lab Invest. 2008, 88: 1038-1048. 10.1038/labinvest.2008.73.

    Article  CAS  PubMed  Google Scholar 

  38. Patel NS, Brancaleone V, Renshaw D, Rocha J, Sepodes B, Mota-Filipe H, Perretti M, Thiemermann C: Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: an in vivo study. Eur J Pharmacol. 2009, 606: 205-209. 10.1016/j.ejphar.2009.01.041.

    Article  PubMed  Google Scholar 

  39. Sivarajah A, McDonald MC, Thiemermann C: The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. Shock. 2006, 26: 154-161. 10.1097/01.shk.0000225722.56681.64.

    Article  CAS  PubMed  Google Scholar 

  40. Jha S, Calvert JW, Duranski MR, Ramachandran A, Lefer DJ: Hydrogen sulfide attenuates hepatic ischemia-reperfusion injury: role of antioxidant and antiapoptotic signaling. Am J Physiol Heart Circ Physiol. 2008, 295: H801-H806. 10.1152/ajpheart.00377.2008.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Sodha NR, Clements RT, Feng J, Liu Y, Bianchi C, Horvath EM, Szabó C, Sellke FW: The effects of therapeutic sulfide on myocardial apoptosis in response to ischemia-reperfusion injury. Eur J Cardiothorac Surg. 2008, 33: 906-913. 10.1016/j.ejcts.2008.01.047.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the Association de Recherche en Réanimation Médicale et Médecine Hyperbare (Angers, France) for financial support, P. Legras and J. Roux for animal care, M. Gonnet for NaHS conditioning, and Ph. Lane, C. Hoffmann and P. Pothier for English proofreading.

Author information

Authors and Affiliations

  1. Laboratoire HIFIH, UPRES EA 3859, IFR 132, Université d'Angers, Rue Haute de Reculée, Angers, F-49035, France

    Frédérique Ganster, Mélanie Burban, Mathilde de la Bourdonnaye, Lionel Fizanne, Olivier Douay, Alain Mercat, Paul Calès & Pierre Asfar

  2. Département de Réanimation Médicale et de Médecine Hyperbare, Centre Hospitalo- Universitaire, 4 rue Larrey, Angers, F-49035, France

    Frédérique Ganster, Alain Mercat, Paul Calès, Pierre Asfar & Ferhat Meziani

  3. INSERM UMR 771; CNRS UMR 6214;, Université d'Angers, Rue Haute de Reculée, Angers, F-49035, France

    Laurent Loufrani & Daniel Henrion

  4. Sektion Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Klinik für Anästhesiologie, Universitätsklinikum, Parkstrasse 11, Ulm, D-89073, Germany

    Peter Radermacher

  5. Laboratoire de Biophotonique et Pharmacologie, UMR 7213 CNRS, Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, Illkirch, F-67401, France

    Ferhat Meziani

  6. Service de Réanimation Médicale, Nouvel Hôpital Civil. Hôpitaux Universitaires de Strasbourg, 1, place de l'Hôpital, F-67031, Strasbourg, France

    Frédérique Ganster & Ferhat Meziani

Authors
  1. Frédérique Ganster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mélanie Burban
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mathilde de la Bourdonnaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lionel Fizanne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olivier Douay
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laurent Loufrani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alain Mercat
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Paul Calès
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peter Radermacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daniel Henrion
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Pierre Asfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ferhat Meziani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Asfar.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

FG participated in the surgical procedure, in in vitro measurements and in the design of the protocol, and drafted the manuscript. MB carried out the Western blotting. MdlB and LF carried out the surgical procedure and in vitro measurements. OD participated in the laboratory investigations. AM, PC and DH helped to design the study. PR helped to design the study and to draft the manuscript. LL participated in in vitro measurements. PA designed the study, and coordinated and drafted the manuscript. FM participated in the design of the study, performed the statistical analysis and helped to draft the manuscript.

Authors’ original submitted files for images

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ganster, F., Burban, M., de la Bourdonnaye, M. et al. Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats. Crit Care 14, R165 (2010). https://doi.org/10.1186/cc9257

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/cc9257

Keywords

Comments

Critical Care

ISSN: 1364-8535